T. Rowe Price Investment Management, Inc. Crinetics Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $164 Billion
- Q3 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 60,584 shares of CRNX stock, worth $2.64 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,584
Previous 716,172
91.54%
Holding current value
$2.64 Million
Previous $20.6 Million
87.75%
% of portfolio
0.0%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding CRNX
# of Institutions
246Shares Held
92.8MCall Options Held
1.02MPut Options Held
204K-
Vanguard Group Inc Valley Forge, PA9.17MShares$399 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.38MShares$365 Million0.06% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.48MShares$282 Million2.29% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$271 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA5.77MShares$251 Million1.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.34B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...